Tirzepatide Cost in 2026: Real Prices & How to Save
Tirzepatide Cost in 2026: Real Prices & How to Save
A pharmacy quote of $1,112 for four injection pens is the number that sends most people searching. It's a real price — Eli Lilly's list price for a 28-day supply — and it's also the number almost nobody paying cash in 2026 actually needs to pay.
The tirzepatide cost you end up with depends less on your pharmacy than on which of four buying channels you use, and which of the two brand names your prescription is written for. Those two decisions can swing your monthly bill by more than $700.
At a glance
- Tirzepatide is sold in the US only as Mounjaro (type 2 diabetes) and Zepbound (weight management and sleep apnea) — there is no generic
- Retail list prices run roughly $1,060 to $1,112 a month, and walk-in cash prices at major chains have landed anywhere from $995 to $1,425
- Manufacturer self-pay pricing is far lower: $299 to $449 a month for Zepbound by dose, and a flat $499 a month for Mounjaro
- Licensed cash-pay networks have listed Mounjaro KwikPens near $349 and Zepbound KwikPens near $400 per pen
- The key US tirzepatide patent runs to January 2036, so a true generic is not close
How much does tirzepatide cost?
Tirzepatide is the active ingredient, not the product you buy. Lilly sells it under two labels: Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in people with obesity. Same molecule, same dose strengths, same weekly injection. Different paperwork, and different prices.
Four channels sell it, and the spread between them is the whole story.
| Channel | Mounjaro / month | Zepbound / month |
|---|---|---|
| Manufacturer list price | ~$1,112 | ~$1,060–$1,086 |
| Walk-in retail cash (CVS, Walgreens, Walmart, Costco) | ~$1,299–$1,425 | ~$995–$1,305 |
| Manufacturer self-pay (LillyDirect) | $499 flat, all strengths | $299–$449 by dose |
| Licensed cash-pay network | ~$349 per KwikPen | ~$400 per KwikPen |
Prices reflect a 28-day supply of four weekly doses and shift by dose, format, pharmacy, and month. Confirm the live number for your exact strength before you fill.
Two things in that table deserve a second look. Walk-in retail cash prices sometimes run above list price — Costco has quoted Mounjaro near $1,425 against a $1,112 list. And the cheapest row isn't the manufacturer. It's the cash-pay pharmacy channel, which almost no article on this topic mentions at all.
Tirzepatide price by dose — and the cliff at 7.5 mg
Nearly every cash program prices tirzepatide by dose strength, which means your monthly bill climbs as you titrate up. Here's how the manufacturer self-pay tiers break down, with the cost-per-milligram math nobody bothers to run.
| Weekly dose | Total mg / month | Zepbound self-pay | Cost per mg |
|---|---|---|---|
| 2.5 mg | 10 mg | $299 | $29.90 |
| 5 mg | 20 mg | $399 | $19.95 |
| 7.5 mg | 30 mg | $449 | $14.97 |
| 10 mg | 40 mg | $449 | $11.23 |
| 12.5 mg | 50 mg | $449 | $8.98 |
| 15 mg | 60 mg | $449 | $7.48 |
The price stops climbing at 7.5 mg. Every strength from there to 15 mg costs the same $449. So the drug gets dramatically cheaper per milligram the higher you go — $7.48 at the top dose versus $29.90 at the starting dose, a four-fold difference.
That matters practically. If your prescriber is deciding between holding you at 7.5 mg and moving you to 10 mg, cost is not the deciding factor — the monthly bill is identical. Plenty of people assume a dose increase means a price increase and don't raise the question. Above 5 mg, it usually doesn't.
Mounjaro works differently: $499 flat at every strength through LillyDirect. That makes it the more expensive choice at low doses and the simpler one to budget for.
Savings tip: Some manufacturer self-pay programs require you to refill within a set window — often 45 days — or your price resets to a higher tier. If a shipping delay or a travel month pushes you past it, call before you reorder rather than letting the system reprice you.
What a full year of tirzepatide actually costs
Monthly prices hide the real number. Standard titration starts at 2.5 mg for four weeks, steps to 5 mg for four weeks, then climbs in 2.5 mg increments as tolerated toward a maintenance dose. Run twelve months of that through each channel and the gaps get much larger than the per-month tables suggest.
| Route (Zepbound, titrating to maintenance) | Year one total |
|---|---|
| Retail list price (~$1,086/mo) | ~$13,032 |
| Manufacturer self-pay ($299 → $399 → $449) | ~$5,188 |
| Cash-pay network (~$400 per pen, flat) | ~$4,800 |
| Route (Mounjaro) | Year one total |
|---|---|
| Retail list price (~$1,112/mo) | ~$13,344 |
| Manufacturer self-pay ($499 flat) | ~$5,988 |
| Cash-pay network (~$349 per pen) | ~$4,188 |
About $9,000 a year separates the top row from the bottom one. Same drug, same dose, same prescription.
The flat-price channels win over a year precisely because they don't reprice you at every titration step. A $400 pen costs more than a $299 starting vial in month one and less than a $449 maintenance refill in months three through twelve. Comparing starting prices is how people talk themselves into the more expensive year.
Tirzepatide cost with insurance
Coverage splits sharply along the brand line, and it's the single biggest driver of what insured patients pay.
Mounjaro is billed as a diabetes drug. Most commercial plans cover diabetes medications, so with a type 2 diabetes diagnosis, an A1C on file, and documented prior therapy, Mounjaro often clears prior authorization. Your cost is then your plan's copay or coinsurance — which, if you haven't met your deductible, can still be the full negotiated price for the first several months of the year.
Zepbound is billed as a weight-loss drug, and a large share of commercial plans exclude that category outright. When coverage exists, it typically requires a documented BMI, a history of weight-management attempts, and a related condition. The obstructive sleep apnea approval has opened some doors, though plans handle it unevenly.
Does Medicare cover tirzepatide?
As of July 1, 2026, CMS runs a temporary pilot called the Medicare GLP-1 Bridge, scheduled to end December 31, 2027. Eligible Part D beneficiaries pay a flat $50 a month regardless of dose.
The fine print matters here more than most coverage summaries admit:
- Only the Zepbound KwikPen qualifies. Single-dose vials and single-dose pens are excluded.
- Mounjaro is not in the program at all, because it's approved for diabetes rather than weight loss.
- The $50 payment sits outside the standard Part D benefit, so it doesn't count toward your deductible or the annual out-of-pocket cap.
Outside the Bridge, most Part D and Medicare Advantage plans still decline tirzepatide for weight loss. Part D may cover Zepbound for sleep apnea or Mounjaro for type 2 diabetes, subject to the plan's formulary and prior authorization rules.
Medicaid varies by state. As of early 2026, roughly 13 states covered GLP-1 medications for weight loss; many more cover tirzepatide when it's prescribed for diabetes.
Compounded tirzepatide cost — and why the cheap numbers are fading
Compounded tirzepatide still posts the lowest advertised prices, generally $200 to $600 a month, sometimes bundled with a telehealth membership fee on top.
The regulatory ground under that option has been shifting for two years. The FDA declared the tirzepatide shortage resolved in October 2024, which removed the main legal basis for mass compounding. On April 30, 2026, the agency proposed striking semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list — a change that would end large-scale compounding of these drugs. Patient-specific 503A compounding remains legal in narrower circumstances, generally where a documented clinical need can't be met by an FDA-approved version.
Compounded medications are not FDA-approved. They haven't gone through the agency's review for safety, effectiveness, or manufacturing consistency, and quality varies between facilities.
Savings tip: Before committing to a compounded plan mid-titration, ask the clinic in writing what happens to your prescription if the 503B rule is finalized. A $250 plan that ends at month four can cost you more than a $399 plan you can stay on, because restarting tirzepatide usually means re-titrating from the bottom dose and paying for those weeks twice.
Is there a generic tirzepatide?
No, and it isn't close.
There is no FDA-approved generic tirzepatide sold in the United States. Anything marketed as "generic tirzepatide" is a compounded preparation, which is a different regulatory category entirely.
The core US patent covering tirzepatide doesn't expire until January 5, 2036. Device and formulation patents could extend practical exclusivity further, toward 2039 for some presentations. The FDA has accepted abbreviated new drug applications from Sandoz and from an Amneal/Adalvo partnership for review, which is a procedural step, not an approval — any launch would still require winning or settling patent litigation, or waiting for the patents to run out.
Treat anyone promising generic tirzepatide pricing in 2026 or 2027 with real skepticism.
Cheaper alternatives to tirzepatide
If $400 a month is out of reach, there are FDA-approved options at lower price points. The trade-off is usually efficacy, and it's worth seeing both numbers side by side.
| Medication (ingredient) | Approved for | Typical cash price / mo | Avg. weight reduction in trials |
|---|---|---|---|
| Tirzepatide (Mounjaro, Zepbound) | Diabetes / weight, OSA | $349–$499 | ~20.9% over 72 weeks |
| Semaglutide (Ozempic, Wegovy) | Diabetes / weight | ~$250–$349 | ~15% over 68 weeks |
| Semaglutide, oral (Rybelsus) | Diabetes | ~$212 (30 tabs) | n/a (diabetes indication) |
| Orforglipron (Foundayo), oral | Weight | $149–$299 | ~11% over 72 weeks |
| Liraglutide (Saxenda, Victoza) | Weight / diabetes | ~$154–$470 | ~8% |
| Dulaglutide (Trulicity) | Diabetes | ~$455 (4-pen pack) | n/a (diabetes indication) |
| Metformin | Diabetes | ~$52 (100 tabs) | modest, not approved for weight loss |
Weight-reduction figures come from each drug's pivotal trials at the highest studied dose, and individual results vary widely.
The math cuts both ways. Ozempic at roughly $250 a month on a two-pen pack is meaningfully cheaper than tirzepatide and produces around three-quarters of the average weight reduction. Oral Rybelsus at about $212 for a 30-tablet month is the lowest-cost brand-name semaglutide if you have diabetes and prefer a pill. Saxenda is the only drug in the class with a true authorized generic, and liraglutide's generic prices start near $154 — but it's a daily injection delivering roughly a third of tirzepatide's average result. Trulicity sits in the same price band as tirzepatide without the weight-loss indication. And metformin at about $52 for 100 tablets is in a different universe on price, and a different universe on what it does.
None of these are interchangeable. Doses don't convert between molecules, and switching without re-titrating can cause significant side effects. Bring the comparison to your prescriber rather than acting on it.
For a fuller breakdown across the whole class, see our guides to GLP-1 cost without insurance and the cheapest GLP-1 without insurance.
How to lower what you pay for tirzepatide
Start with the brand question, because it's the lever with the biggest swing. If you have type 2 diabetes, Mounjaro is the on-label choice and it's the one your plan is far more likely to cover. If you don't, Zepbound is the appropriate prescription and the cash-pay routes become your main path. Ask your prescriber which brand your diagnosis supports — getting the label wrong is the fastest route to a coverage denial.
Price all four channels for your exact strength and format. A quote for 2.5 mg tells you nothing about 10 mg, and a vial price tells you nothing about a KwikPen price.
Do the pack math before you compare. Mounjaro and Zepbound KwikPens each cover four weekly doses, so one pen is one month. Other GLP-1s don't work that way — a Trulicity pack is four pens for one month, a Saxenda pack is five pens for one month, and an Ozempic 1 mg two-pen pack covers about two months. Comparing sticker prices without dividing by duration is how people rule out the cheaper option.
Price your likely maintenance dose, not your starting dose, then multiply by twelve and add any recurring membership or consultation fee. The cheapest first month and the cheapest year are frequently different products.
And re-check every few months. Tirzepatide pricing has moved more in the last eighteen months than in the prior five years. A quote from January 2026 is already stale.
Savings tip: If cost is the reason you'd stop taking tirzepatide, say that plainly at your appointment. Prescribers can often write for a different format, hold you at a maintenance dose that prices better, or move you to a different molecule — but only if they know money is the constraint. Never stretch pens, split doses, or skip weeks to save money.
The bottom line
Tirzepatide lists for roughly $1,060 to $1,112 a month and can be quoted higher than that at a retail counter. Paying cash in 2026, the realistic range is $299 to $499 a month through manufacturer self-pay, or closer to $349 to $400 per pen through a licensed cash-pay network — about $4,200 to $6,000 for a full year instead of $13,000.
Work out which brand your diagnosis supports, price your expected maintenance dose across every channel, and confirm the live number before each fill. If you want the brand-by-brand detail, our Mounjaro cost guide and Zepbound cost guide go deeper, and Zepbound vs Mounjaro covers how the two labels differ.
Frequently asked questions
How much does tirzepatide cost per month?
Without insurance, expect $1,060 to $1,112 a month at list price, or higher at some retail counters. Through manufacturer self-pay, Zepbound runs $299 to $449 depending on dose and Mounjaro is $499 flat. Licensed cash-pay networks have listed Mounjaro KwikPens near $349 and Zepbound KwikPens near $400 per 28-day pen.
What is the cheapest way to get tirzepatide?
For most cash payers, the lowest sustained price comes from a licensed cash-pay pharmacy network, where flat per-pen pricing avoids the dose-based increases built into manufacturer programs. Manufacturer self-pay is cheapest for the first month or two at the 2.5 mg starting dose. Compounded tirzepatide advertises lower still, but it isn't FDA-approved and its availability is narrowing under 2026 rules.
Is tirzepatide cheaper with insurance than paying cash?
Sometimes, and sometimes not. If your plan covers the brand you're prescribed and you've met your deductible, insurance usually wins. If the drug is excluded, or you're early in the plan year with a high deductible, a cash price near $349 to $449 can beat what your plan would charge you. Price both before you fill.
Do Costco or Walmart have a cheaper tirzepatide price?
Not reliably. Reported walk-in cash prices at major chains have ranged from about $995 to $1,425 a month, and some have run above the manufacturer's list price. Chain pricing moves by location and week, so it's worth checking, but it rarely competes with manufacturer self-pay or cash-pay network pricing.
Why is there no generic tirzepatide?
The key US patent on tirzepatide doesn't expire until January 5, 2036, with device and formulation patents potentially extending exclusivity further. Sandoz and an Amneal/Adalvo partnership have had generic applications accepted for FDA review, but acceptance isn't approval, and any launch would require resolving patent litigation first. Products advertised as "generic tirzepatide" today are compounded, not FDA-approved generics.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.